Nordimet

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Metotreksat

Available from:

Nordic Group B.V.

ATC code:

L04AX03

INN (International Name):

methotrexate

Therapeutic group:

Antineoplastična sredstva

Therapeutic area:

Arthritis, Psoriatic; Psoriasis; Arthritis, Juvenile Rheumatoid; Arthritis, Rheumatoid

Therapeutic indications:

Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.

Product summary:

Revision: 22

Authorization status:

Pooblaščeni

Authorization date:

2016-08-18

Patient Information leaflet

                                28
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP:
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25 °C.
Peresnike shranjujte v zunanji ovojnini za zagotovitev zaščite pred
svetlobo.
Ne zamrzujte.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z
lokalnimi predpisi.
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Nordic Group B.V.
Siriusdreef 41
2132 WT Hoofddorp
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/16/1124/001 1 napolnjen injekcijski peresnik
EU/1/16/1124/057 4 napolnjeni injekcijski peresniki
13.
ŠTEVILKA SERIJE
Lot:
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Nordimet 7,5 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
29
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
30
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA ZA SKUPNO PAKIRANJE (S PODATKI MODREGA OKENCA)
1.
IME ZDRAVILA
Nordimet 7,5 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
metotreksat
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
En napolnjen injekcijski peresnik z 0,3 ml raztopine vsebuje 7,5 mg
metotreksata (25 mg/ml).
3.
SEZNAM POMOŽNIH SNOVI
natrijev klorid
natrijev hidroksid
voda za injekcije
4.
FARMACEVTSKA OBLIKA IN VSEBINA
raztopina za injiciranje
7,5 mg/0,3 ml
Skupno pakiranje: 4 (4 pakiranja po 1) napolnjeni injekcijski
peresniki (0,3 ml) in 4 alkoholne
blazinice
Skupno pakiranje: 6 (6 pakiranj po 1) napolnjenih injekcijskih
peresnikov (0,3 ml) in 6 alkoholnih
blazinic
Skupno pakiranje: 12 (3 pakiranja po 4) napolnjenih injekcijskih
peresnikov (0,3 ml) in 12 alkoholnih
blazinic
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
subkutana uporaba
Metotreksat se injicira enkrat tedensko.
Pred uporabo preberite priloženo navodilo!
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otro
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1
IME ZDRAVILA
Nordimet 7,5 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
Nordimet 10 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
Nordimet 12,5 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
Nordimet 15 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
Nordimet 17,5 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
Nordimet 20 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
Nordimet 22,5 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
Nordimet 25 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
Nordimet 7,5 mg raztopina za injiciranje v napolnjeni injekcijski
brizgi
Nordimet 10 mg raztopina za injiciranje v napolnjeni injekcijski
brizgi
Nordimet 12,5 mg raztopina za injiciranje v napolnjeni injekcijski
brizgi
Nordimet 15 mg raztopina za injiciranje v napolnjeni injekcijski
brizgi
Nordimet 17,5 mg raztopina za injiciranje v napolnjeni injekcijski
brizgi
Nordimet 20 mg raztopina za injiciranje v napolnjeni injekcijski
brizgi
Nordimet 22,5 mg raztopina za injiciranje v napolnjeni injekcijski
brizgi
Nordimet 25 mg raztopina za injiciranje v napolnjeni injekcijski
brizgi
2
KAKOVOSTNA IN KOLIČINSKA SESTAVA
1 ml raztopine vsebuje 25 mg metotreksata.
Nordimet 7,5 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
En napolnjen injekcijski peresnik vsebuje 7,5 mg metotreksata v 0,3
ml.
Nordimet 10 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
En napolnjen injekcijski peresnik vsebuje 10 mg metotreksata v 0,4 ml.
Nordimet 12,5 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
En napolnjen injekcijski peresnik vsebuje 12,5 mg metotreksata v 0,5
ml.
Nordimet 15 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
En napolnjen injekcijski peresnik vsebuje 15 mg metotreksata v 0,6 ml.
Nordimet 17,5 mg raztopina za injiciranje v napolnjenem injekcijskem
peresniku
En napolnjen injek
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 29-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 29-02-2024
Public Assessment Report Public Assessment Report Bulgarian 20-11-2023
Patient Information leaflet Patient Information leaflet Spanish 29-02-2024
Public Assessment Report Public Assessment Report Spanish 20-11-2023
Patient Information leaflet Patient Information leaflet Czech 29-02-2024
Public Assessment Report Public Assessment Report Czech 20-11-2023
Patient Information leaflet Patient Information leaflet Danish 29-02-2024
Public Assessment Report Public Assessment Report Danish 20-11-2023
Patient Information leaflet Patient Information leaflet German 29-02-2024
Public Assessment Report Public Assessment Report German 20-11-2023
Patient Information leaflet Patient Information leaflet Estonian 29-02-2024
Public Assessment Report Public Assessment Report Estonian 20-11-2023
Patient Information leaflet Patient Information leaflet Greek 29-02-2024
Public Assessment Report Public Assessment Report Greek 20-11-2023
Patient Information leaflet Patient Information leaflet English 31-10-2019
Public Assessment Report Public Assessment Report English 31-10-2019
Patient Information leaflet Patient Information leaflet French 29-02-2024
Public Assessment Report Public Assessment Report French 20-11-2023
Patient Information leaflet Patient Information leaflet Italian 29-02-2024
Public Assessment Report Public Assessment Report Italian 20-11-2023
Patient Information leaflet Patient Information leaflet Latvian 29-02-2024
Public Assessment Report Public Assessment Report Latvian 20-11-2023
Patient Information leaflet Patient Information leaflet Lithuanian 29-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 29-02-2024
Public Assessment Report Public Assessment Report Lithuanian 20-11-2023
Patient Information leaflet Patient Information leaflet Hungarian 29-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 29-02-2024
Public Assessment Report Public Assessment Report Hungarian 20-11-2023
Patient Information leaflet Patient Information leaflet Maltese 29-02-2024
Public Assessment Report Public Assessment Report Maltese 20-11-2023
Patient Information leaflet Patient Information leaflet Dutch 29-02-2024
Public Assessment Report Public Assessment Report Dutch 20-11-2023
Patient Information leaflet Patient Information leaflet Polish 29-02-2024
Public Assessment Report Public Assessment Report Polish 20-11-2023
Patient Information leaflet Patient Information leaflet Portuguese 29-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 29-02-2024
Public Assessment Report Public Assessment Report Portuguese 20-11-2023
Patient Information leaflet Patient Information leaflet Romanian 29-02-2024
Public Assessment Report Public Assessment Report Romanian 20-11-2023
Patient Information leaflet Patient Information leaflet Slovak 29-02-2024
Public Assessment Report Public Assessment Report Slovak 20-11-2023
Patient Information leaflet Patient Information leaflet Finnish 29-02-2024
Public Assessment Report Public Assessment Report Finnish 20-11-2023
Patient Information leaflet Patient Information leaflet Swedish 29-02-2024
Public Assessment Report Public Assessment Report Swedish 20-11-2023
Patient Information leaflet Patient Information leaflet Norwegian 29-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 29-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 29-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 29-02-2024
Patient Information leaflet Patient Information leaflet Croatian 29-02-2024
Public Assessment Report Public Assessment Report Croatian 20-11-2023

Search alerts related to this product

View documents history